OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
26 nov. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
30 oct. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
23 oct. 2024 07h00 HE
|
OKYO Pharma LTD
OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trialThe Phase 2 trial is designed as a randomized, placebo-controlled,...
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
16 oct. 2024 07h00 HE
|
OKYO Pharma LTD
Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The...
OKYO Pharma Announces Chairman Acquires Shares
10 sept. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Announces Chairman Acquires Shares
05 sept. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
27 août 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma CEO Interview to Air on Bloomberg TV
23 août 2024 09h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Announces Chairman Acquires Shares
23 août 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OKYO Pharma Announces Chairman Acquires Shares
21 août 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...